Canada's Biotechnology Industry Faces Challenges Amid Government Support

Despite government support and a strong scientific base, Canada's biotechnology industry is struggling to secure private sector investment, prompting fears of consolidation and potential business failures. The industry has grown rapidly since its inception, with around 280 biotechnology companies established in the country. However, most of these companies remain small-scale, and there is a severe shortage of funds available for growth. This has led to calls for consolidation in the industry, as well as concerns about the lack of management expertise and access to public markets.

Key Takeaways:

The Canadian biotechnology industry has grown rapidly, with around 280 companies established in the country, mainly in regions around Montreal, Quebec City, and Toronto.
The industry has received generous government support, including tax concessions and public spending on laboratories and infrastructure, particularly in Quebec.
However, most Canadian biotechnology companies remain small-scale, and there is a severe shortage of funds available for growth, making it difficult for them to attract private sector investment.
Many companies are struggling to access public markets via initial public offerings (IPOs), with some facing potential business failures due to lack of funding.
The industry is in need of consolidation, with experts calling for companies to merge in order to become more competitive and attract larger investments.
Canada's biotechnology industry faces challenges in attracting and retaining top management talent, with many companies looking abroad for expertise.
The industry has received significant public sector funding, including a $500m investment in genomic research institutes, but this may not be enough to support the growth of smaller companies.
The relationship between public sector funding and private sector investment is complex, with some investors arguing that the link between the two is key to the industry's success.

Statistics:

280 biotechnology companies are established in Canada (mainly in regions around Montreal, Quebec City, and Toronto)
BioChem Pharma from Quebec has a market capitalization of C$3.6bn (making it Canada's leading biotech company)
Income tax rates for high-earners in Canada can reach 50%
The Canadian government has waived income tax for business chiefs working in high-technology industries in Quebec for the first five years.
The public sector has invested $500m in setting up three new genomic research institutes across Canada in the next five years.
Venture capitalists have tied themselves to the government, providing patient capital, easier to access than in the US (reportedly).

Sources:

Canadian biotech industry conference, where Robert Esposito, a healthcare and life sciences expert at KPMG, called for consolidation.
Interview with Martin Godbout, president of BioContact, the Quebec biotech forum.
Interview with Gervaise Dionne, executive vice-president of BioChem Pharma.